Chul Kim

7

9

604

Chul Kim retweetledi

Balazs Halmos@BalazsHalmosMD·3d

Great start with an amazing inaugural @iaslc Leadership Development Program class from all across the globe kicked off by wonderful presentations by no other than Drs. Kelly and Ben Solomon! We learned among other things that some time you need to step off the clinical conveyor belt to focus on developing additional skills and that career paths are rarely linear. Special thanks to all our mentors sacrificing their precious time to support our class/program- they are clearly ones who lead by example! @chulkimMD @tnewsomdavis @clarissamathias @RielyMD amd terrific co-chairs @drsabita , Marie-Liesse Asselin-Labat and Deebya Mishra

English

Balazs Halmos@BalazsHalmosMD

3

18

1.3K

Chul Kim@chulkimMD·3d

It is an honor to be part of the inaugural IASLC Leadership Development Program. I feel fortunate to have Dr. @RielyMD as my mentor. During the first session, we explored key attributes of effective leadership. Learning directly from mentors’ experiences was valuable. Thank you to the program chairs, IASLC staff, and mentors from across the globe for putting together an outstanding program. @BalazsHalmosMD @IASLC @LombardiCancer

Great start with an amazing inaugural @iaslc Leadership Development Program class from all across the globe kicked off by wonderful presentations by no other than Drs. Kelly and Ben Solomon! We learned among other things that some time you need to step off the clinical conveyor belt to focus on developing additional skills and that career paths are rarely linear. Special thanks to all our mentors sacrificing their precious time to support our class/program- they are clearly ones who lead by example! @chulkimMD @tnewsomdavis @clarissamathias @RielyMD @drsabita

English

6

280

Chul Kim@chulkimMD·11 Mar

@motherofswans @ROsarogiagbon Hope we will have fully validated blood based assays in the future!

English

0

1

5

Mother of Swans@motherofswans·8 Mar

@chulkimMD @ROsarogiagbon And you can find out if you have lung nodules without a ct.

English

0

1

10

Chul Kim@chulkimMD·7 Mar

Lung cancer screening is still underused, and many patients have prior healthcare encounters before diagnosis. Lung nodule programs can help bridge this gap, and emerging AI tools like #Sybil may further enhance risk prediction from CT scans. @ROsarogiagbon #OKTO26

English

2

8

824

Chul Kim retweetledi

Stephen V Liu, MD@StephenVLiu·9 Mar

We are looking for a classical benign hematologist to join our faculty at the @LombardiCancer @MedStarGUH! One of many clinical & research opportunities here at the only NCI designated Comprehensive Cancer Center in Washington, DC. See link for details: careers.medstarhealth.org/careers-home/j…

English

8

11

2.6K

Chul Kim retweetledi

Laura Alder, MD@LauraAlderMD·8 Mar

Thankful to be a part of the #NYLCF26, fostering meaningful conversations with a call to action for improved policies, trial design, and building partnerships. Great seeing inspiring friends and colleagues! #NewYorkLungCancerFoundationSummit @peters_solange @fred_hirsch @Latinamd @JSabari @HwakeleeMD @JhanelleGray @JulieBrahmer @maraantonoff

English

8

18

1.4K

Chul Kim retweetledi

Rafeh Naqash, MD, FASCO@thenasheffect·8 Mar

Thanks a wrap! Fun times with the gang at OKcThoracic @binaytara. Was great having everyone discussing and exchanging ideas in lung cancer !

English

4

29

2.2K

Chul Kim@chulkimMD·8 Mar

How should we manage oligometastatic & oligoprogressive NSCLC? Growing evidence supports local therapy in carefully selected patients. Key questions remain: -Definition of these states -Who truly benefits -Best local therapy modality Insightful talk by @BRicciutiMD #OKTO26

English

6

24

1.7K

Chul Kim@chulkimMD·7 Mar

#Tarlatamab is reshaping the treatment landscape in SCLC. From relapsed disease (combination with ADC) to potential earlier line strategies (DeLLphi-305, 306, 312), multiple trials are underway. Eagerly awaiting the results from these studies. @thenasheffect @binaytara #OKTO26

English

16

33

1.7K

Chul Kim@chulkimMD·7 Mar

Encouraging momentum in SCLC: #durvalumab consolidation for LS-SCLC, #lurbinectedin maintenance for 1st line ES-SCLC, and #tarlatamab in the 2L+ setting for ES-SCLC. Progress being made in a historically challenging disease. @NaglaAKarimMD #OKTO26 @BCAppelbaum

English

3

16

840

Chul Kim retweetledi

Aadel Chaudhuri, MD PhD@aadel_chaudhuri·7 Mar

Heck of a fun debate on ctDNA in early-stage NSCLC! And I still can’t believe I lost the debate to a fellow — the very talented @AminNassarMD @YaleMed. Proof that the next generation of physician-scientists are as bright as they come & are coming for all of us!! #OKTO26

Chul Kim@chulkimMD

Educational debate on utility of ctDNA in early-stage NSCLC #OKTO26 ctDNA is emerging as a strong prognostic biomarker - is it ready for prime time in clinical decision-making? What additional data do we need to move from detection to action? @AminNassarMD @aadel_chaudhuri

English

5

25

6.1K

Chul Kim@chulkimMD·7 Mar

@ClayReedMD @binaytara @NIH It was great to connect with you! Thanks for the kind invitation.

English

12

Chul Kim retweetledi

Clay Reed, MD@ClayReedMD·7 Mar

@chulkimMD did an incredible job kicking us off today at @binaytara #OKTO26 covering perioperative treatment and importance of pCR. Several @NIH heme/onc fellow alumni here today in OKC!

English

6

16

662

Chul Kim@chulkimMD·7 Mar

ADCs are reshaping the Tx landscape in NSCLC • Activity across multiple targets (HER2, MET, TROP2) • Variable correlation between target expression and efficacy Can ADCs replace docetaxel in 2L? Yes - but better target selection & ADC design needed. @FawziAbuRous #OKTO26

English

19

52

3.1K

Chul Kim@chulkimMD·7 Mar

Educational debate on utility of ctDNA in early-stage NSCLC #OKTO26 ctDNA is emerging as a strong prognostic biomarker - is it ready for prime time in clinical decision-making? What additional data do we need to move from detection to action? @AminNassarMD @aadel_chaudhuri

English

6

21

5.7K

Chul Kim retweetledi

Dr. Nagla Abdel Karim@NaglaAKarimMD·7 Mar

It was a great pleasure giving the keynote session on KRAS in NSCLC; Drive to targeted therapies-Current insights ⁦@thenasheffect⁩ ⁦@chulkimMD⁩ #2026 Oklahoma Thoracic Oncology Conference.

English

7

10

579

Chul Kim@chulkimMD·7 Mar

KRAS mutations were historically considered undruggable. Now we have approved inhibitors for KRAS G12C (sotorasib, adagrasib) & a broad array of agents in development from variant-specific inhibitors beyond G12C to pan-KRAS/RAS strategies. Exciting time. @NaglaAKarimMD #OKTO26

English

13

39

2.1K

Chul Kim retweetledi

Dr. Nagla Abdel Karim@NaglaAKarimMD·7 Mar

Happening now; great case discussion session on Neoadjuvant/adjuvant therapies in NSCLC ⁦@thenasheffect⁩ 2026 Oklahoma Thoracic Oncology Conference

English

4

8

595

Chul Kim@chulkimMD·7 Mar

In EGFR mutant NSCLC, with amivantamab + lazertinib, patterns of acquired resistance appear to shift, with less EGFR- and MET-driven resistance. Supportive care matters (SKIPPirr, COCOON). SubQ amivantamab is an exciting next step. Insightful talk by @YYElamin @binaytara

English